v3.26.1
Unaudited Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses    
Research and development (including $1,375,000 for the three months ended March 31, 2026 and 2025, from related party) $ 1,400,275 $ 1,410,188
General and administrative (including $69,946 and $ 64,433 for the three months ended March 31, 2026 and 2025, respectively, from related parties) 891,789 694,110
Total operating expenses 2,292,064 2,104,298
Loss from Operations (2,292,064) (2,104,298)
Loss before income tax (2,292,064) (2,104,298)
Income tax provision (13)
Net loss $ (2,292,064) $ (2,104,311)
Net loss applicable to common stock per share, basic (in Dollars per share) $ (0.05) $ (0.06)
Net loss applicable to common stock per share, diluted (in Dollars per share) $ (0.05) $ (0.06)
Weighted average common stock outstanding, basic (in Shares) 42,121,075 36,188,293
Weighted average common stock outstanding, diluted (in Shares) 42,121,075 36,188,293